CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Francisco J Esteva¹ , Jing Wang² , Feng Lin² , Jaime A Mejia¹ , Kai Yan² , Kadri Altundag^1,3 , Vicente Valero¹ , Aman U Buzdar¹ , Gabriel N Hortobagyi¹ , W Fraser Symmans⁴ and Lajos Pusztai¹

¹  Department of Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

²  Department of Bioinformatics and Computational Biology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

³  Department of Medical Oncology, Hacettepe University Institute of Oncology, Sihhiye St, Ankara 06100, Turkey

⁴  Department of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA